ArticleFrontiers in immunology2026
Integrative transcriptomics-metabolomics reveals sphingolipid metabolic reprogramming in traditional Chinese medicine syndrome differentiation of rheumatoid arthritis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate sphingolipid metabolism for differentiating heat-dampness syndrome from kidney-liver deficiency syndrome in Rheumatoid Arthritis (RA), identify metabolic biomarkers, and integrate transcriptomic data to elucidate molecular mechanisms. Methods: 40 RA patients (kidney-liver deficiency syndrome, n=20; heat-dampness syndrome, n=20) were enrolled and serum untargeted metabolomics profiling was performed using ultra-performance liquid chromatography-tandem mass spectrometry. A least absolute shrinkage and selection operator logistic regression diagnostic model was constructed, and its performance was assessed by receiver operating characteristic curve and decision curve analyses. Three independent transcriptomic datasets were downloaded from the Gene Expression Omnibus database (GSE55235: 10 RA synovium, 10 osteoarthritis synovium, and 10 normal synovium; GSE93272: RA whole blood and healthy control whole blood; GSE17755: RA peripheral blood mononuclear cells and healthy control peripheral blood mononuclear cells), and differential expression and tissue-specific regulation of sphingolipid-metabolism-related genes were analyzed. Immune cell infiltration was estimated using marker gene set mean expression scoring, and Spearman correlation analysis was used to construct metabolite-clinical indicator networks. Results: Sphingosine kinase 1 activity (sphingosine-1-phosphate/C17-sphinganine ratio) was significantly higher in the heat-dampness syndrome group than in the kidney-liver deficiency syndrome group (P = 3.45×10 Conclusions: C17-sphinganine is a core metabolic biomarker for distinguishing kidney-liver deficiency syndrome from heat-dampness syndrome, enabling precise syndrome classification with a single measurement. The tissue-specific magnitude-difference regulation of sphingosine-1-phosphate lyase 1 and the sphingosine kinase 1-neutrophil correlative trend provide novel insights into how sphingolipid metabolism participates in traditional Chinese medicine syndrome differentiation in RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.